NASDAQ:CHMAChiasma Stock Price, Forecast & News

Chiasma's stock was trading at $3.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHMA stock has increased by 18.4% and is now trading at $4.64.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chiasma.

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Chiasma.

Chiasma Inc (NASDAQ:CHMA) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05.
View Chiasma's earnings history.

3 analysts have issued 1-year price objectives for Chiasma's shares. Their forecasts range from $11.00 to $19.00. On average, they anticipate Chiasma's share price to reach $16.00 in the next year. This suggests a possible upside of 244.8% from the stock's current price.
View analysts' price targets for Chiasma.

Media stories about CHMA stock have been trending negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Chiasma earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Chiasma.

Chiasma saw a decline in short interest in July. As of July 15th, there was short interest totaling 1,830,000 shares, a decline of 15.7% from the June 30th total of 2,170,000 shares. Based on an average daily volume of 752,200 shares, the short-interest ratio is currently 2.4 days. Approximately 4.6% of the shares of the company are short sold.
View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Assembly Biosciences (ASMB), Kura Oncology (KURA), Legend Biotech (AMTI), ImmunoGen (IMGN), Morphic (MORF), Omeros (OMER), Tricida (TCDA), ZIOPHARM Oncology (ZIOP), Frequency Therapeutics (FREQ), Akouos (AKUS), Homology Medicines (FIXX), ORIC Pharmaceuticals (ORIC), Eagle Pharmaceuticals (EGRX), Passage Bio (KROS) and Kadmon (KDMN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX), Alnylam Pharmaceuticals (ALNY), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Progenics Pharmaceuticals (PGNX).

(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by many different institutional and retail investors. Top institutional shareholders include SG Americas Securities LLC (0.05%), ProShare Advisors LLC (0.03%) and UBS Group AG (0.02%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam.
View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Chiasma.

CHMA stock was acquired by a variety of institutional investors in the last quarter, including ProShare Advisors LLC, and SG Americas Securities LLC. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Raj Kannan, Scott Minick, and William Ludlam.
View insider buying and selling activity for Chiasma.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.64.

Chiasma has a market capitalization of $196.11 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]